Effect of tauroursodeoxycholic acid on survival and safety in amyotrophic lateral sclerosis: a retrospective population-based cohort study

BACKGROUND: Oral tauroursodeoxycholic acid (TUDCA) is a commercial drug currently tested in patients with amyotrophic lateral sclerosis (ALS) both singly and combined with sodium phenylbutyrate. This retrospective study aimed to investigate, in a real-world setting, whether TUDCA had an impact on th...

Descripción completa

Detalles Bibliográficos
Autores principales: Zucchi, Elisabetta, Musazzi, Umberto Maria, Fedele, Guido, Martinelli, Ilaria, Gianferrari, Giulia, Simonini, Cecilia, Fini, Nicola, Ghezzi, Andrea, Caputo, Maria, Sette, Elisabetta, Vacchiano, Veria, Zinno, Lucia, Anceschi, Pietro, Canali, Elena, Vinceti, Marco, Ferro, Salvatore, Mandrioli, Jessica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10570688/
https://www.ncbi.nlm.nih.gov/pubmed/37842553
http://dx.doi.org/10.1016/j.eclinm.2023.102256

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10570688/
https://www.ncbi.nlm.nih.gov/pubmed/37842553
http://dx.doi.org/10.1016/j.eclinm.2023.102256

Ejemplares similares